A Phase II Trial of ProLindac and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer

Trial Profile

A Phase II Trial of ProLindac and Paclitaxel Combination as Second Line-Treatment in Platinum Pretreated Patients with Advanced Ovarian Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2015

At a glance

  • Drugs AP 5346 (Primary) ; Paclitaxel
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Access Pharmaceuticals
  • Most Recent Events

    • 24 Jan 2015 Status changed from recruiting to completed, according to European Clinical Trials Database
    • 28 Mar 2012 Planned number of patients changed from 25 to 28 and additional trial location (France) added as reported by European Clinical Trials Database.
    • 03 Nov 2010 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top